Hepatitis C-associated osteosclerosis (HCAO): Report of a new case with involvement of the OPG/RANKL system

Osteoporosis International

Volumn 16, Issue 12, 2005, Pages 2180-2184

  Fiore, C E ^a   Riccobene, S ^a   Mangiafico, R ^a   Santoro, F ^a   Pennisi, P ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Hepatitis C associated osteosclerosis; OPG; RANKL

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AGED; ARTICLE; BONE EXAMINATION; BONE PAIN; BONE REMODELING; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; OSTEOSCLEROSIS; PRIORITY JOURNAL;

AGED; ALKALINE PHOSPHATASE; BONE DENSITY; CARRIER PROTEINS; FEMALE; FEMUR; GLYCOPROTEINS; HEPATITIS C; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; OSTEOSCLEROSIS; PELVIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 29044432953     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1858-8     Document Type: Article

References (22)

1. Choo QL, Weiner AJ, Overby LR (1990) Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 46:423-441
2. Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP (1992) Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 93:371-381
3. Beyer HS, Anderson Q, Shih MS, Parfitt AM, Heath H (1993) Diffuse osteosclerosis in intravenous drug abusers. Am J Med 95:660-661
4. Whyte MP, Teitelbaum SL, Reinus WR (1996) Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11:554-558
5. Diamond T, Depczysnki B (1996) Acquired osteosclerosis associated with intravenous drug use and hepatitis C infection. Bone 19:679-683
6. Whyte MP, Reasner CA (1997) Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med 102:219-229
7. Hassoun AAK, Nippoldt TB, Tiegs RD, Khosla S (1997) Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med 103:70-73
8. Shaker JL, Reims WR, Whyte MP (1998) Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab 83:93-98
9. Wakitani S, Hattori T, Nakaya H, Chae YM, Murata N, Tanigami A (2003) Clinical images: hepatitis C-associated osteosclerosis. Arthritis Rheum 48:268
10. Khosla S, Hassoun AAK, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL (1998) Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. J Clin Invest 101:2165-2173
11. Khosla S, Ballard FJ, Conover CA (2002) Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 87:3867-3870
12. Khosla S (2001) Minireview: the OPG/RANK/RANKL system. Endocrinology 142:5050-5055
13. Shaker JL, Moore BP, Whyte MP (1999) Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 84:384-385
14. Whyte MP, Chines A, Silva DP, Landt Y, Ladenson JH (1996) Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res 11:1438-1443
15. Pennisi P, Signorelli SS, Riccobene S, Celotta G, Di Pino L, La Malfa T, Fiore CE (2004) Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15:389-395
16. Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnock E, Dunkel K, Lakatos P (2003) High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 38:395-400
17. Burgess TL, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538
18. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066
19. Tappero G, Farina M, Negro F, Anfossi G, Mattiello L, Giuli PD, Colombatto P, Brunetto MR, Angeli A, Bonino F (1997) Intrahepatic expression of c-fos, c-myb and c-myc oncogenes: correlation with virus-induced chronic liver disease and response to interferon. Ital J Gastroenterol Hepatol 29:148-154
20. Sabatakos G, Sims NA, Chen K, Aoki K, Kelz MB, Amling M, Bouali V, Mukhopadhyay K, Ford K, Nestler EJ, Baron R (2000) Overexpression of ΔFos B transcription factor(s) increases bone formation and inhibits adipogenesis. Nat Med 6:985-990
21. Jochum W, David JP, Elliot C, Wutz A, Plenk H, Matsuo K, Wagner EF (2000) Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med 6:980-984
22. Matsuo K, Owens JM, Tonko M, Elliot C, Chambers TJ, Wagner EF (2000) Fos-1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184-187